A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2010 by Sheba Medical Center.
Recruitment status was  Recruiting
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
First received: September 14, 2005
Last updated: February 7, 2010
Last verified: February 2010
The primary objective of this multicenter study is to evaluate the efficacy of escitalopram in treatment resistant depression (TRD), assessed by 2 consecutive failed antidepressant treatments from different classes. The last treatment received is a 6 week prospective trial with venlafaxine.

Condition Intervention
Depressive Disorder, Major
Drug: escitalopram

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:
  • MADRS [ Time Frame: 8 to 10 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: February 2005
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: escitalopram
    10 to 30 mg / day

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Any patient who meets all of the following criteria is eligible for inclusion in the Prospective phase I of the study:

  1. The patient is able to read and understand the patient information sheet.
  2. Prior to any screening procedures, the patient must have signed the informed consent form. No study-related procedures may be performed before the patient has signed the form.
  3. The patient is an in- or outpatient, male or female.
  4. The patient is between 18 and 65 years of age.
  5. The patient suffers from a diagnosis of recurrent Major Depressive Disorder (current episode assessed with the MINI), moderate or severe, according to DSM-IV-TR criteria (classification code = 296.3x).
  6. The patient has a total score of 22 or higher on the MADRS.
  7. The patient has been treated for the current episode with an antidepressant (other than escitalopram or venlafaxine) prescribed continuously at the optimal dose (see table Appendix 1) for at least the 4 weeks preceding selection (AD1).
  8. The investigator considers switching treatment to venlafaxine (AD2), prescribing it at its optimal dose, defined by the study protocol.

Exclusion Criteria:

Any patient who meets one or more of the following criteria cannot be included in the screening phase of the study:

  1. The patient has previously participated in this study.
  2. Results from blood sampling at selection show for the antidepressant prescribed (AD1), that plasma concentration is below the expected threshold according to time of last intake.
  3. The patient has taken another antidepressant in combination to the antidepressant to which he/she is considered as non-responder (AD1).
  4. The patient has one or more of the following conditions:

    1. Any current psychiatric disorder established as the principal diagnosis other than Major depressive episode as defined in the DSM-IV-TR (assessed with the MINI).
    2. Any Substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR.
    3. Any severe personality disorder according to investigator clinical judgement, that might compromise the study.
  5. The patient uses disallowed recent or concomitant medication within the specified time periods:

    1. oral antipsychotic drugs within 2 months and depot antipsychotic preparations within the past 6 months.
    2. ECT within the past 6 months.
    3. lithium, carbamazepine, valproate or valpromide within the past month.
    4. any benzodiazepines at a dose higher than 10 mg diazepam or equivalent, within the last week.
    5. any non-benzodiazepine anxiolytics within the last week.
    6. serotonin agonists within the last week.
    7. any other drug with potential psychotropic effects within the last week.
    8. any drug known to lower blood pressure in the last week.
  6. The patient has been treated with any investigational product within 3 months prior to screening.
  7. The patient has been treated during the current episode with escitalopram or venlafaxine.
  8. The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to escitalopram or venlafaxine.
  9. The patient started (or will start) formal psychotherapy in the month preceding inclusion.
  10. The patient has a previous history of convulsive disorder other than a single childhood febrile seizure.
  11. The patient presents evidence of urinary retention or glaucoma.
  12. The patient has a serious illness and/or serious sequelae thereof, including liver or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance.
  13. The patient has, in the opinion of the investigator, on the basis of a physical examination, medical history and vital signs, a comorbid conditions(s) that would render inclusion in the study unsafe.
  14. The patient takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.
  15. The patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00220480

Contact: Leah Fostick, MA +972-3-5357805 Leah.Fostick@sheba.health.gov.il

Rambam Medical Center Recruiting
Haifa, Israel
Contact: Leah Fostick, MA    +972-3-5357805    Leah.Fostick@sheba.health.gov.il   
Ness Ziona Mental Health Center Recruiting
Ness Ziona, Israel
Contact: Leah Fostick, MA    +972-3-5357805    Leah.Fostick@sheba.health.gov.il   
Gehah Mental Health Center Recruiting
Petach Tikva, Israel
Contact: Leah Fostick, MA    +972-3-5357805    Leah.Fostick@health.gov.il   
Chaim Sheba Medical Center Recruiting
Ramat-Gan, Israel, 52621
Contact: Leah Fostick, MA    +972-3-5357805    Leah.Fostick@sheba.health.gov.il   
Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Joseph Zohar, MD Tel Aviv University
  More Information

Responsible Party: Prof. Joseph Zohar, Chaim Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00220480     History of Changes
Other Study ID Numbers: SHEBA-04-3434-JZ-CTIL 
Study First Received: September 14, 2005
Last Updated: February 7, 2010
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Depressive Disorder, Treatment-Resistant
Behavioral Symptoms
Mental Disorders
Mood Disorders
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antiparkinson Agents
Autonomic Agents
Cholinergic Agents
Cholinergic Antagonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors

ClinicalTrials.gov processed this record on May 23, 2016